Syndax Pharmaceuticals Company Insiders

SNDX Stock  USD 16.51  0.01  0.06%   
Syndax Pharmaceuticals employs about 184 people. The company is managed by 18 executives with a total tenure of roughly 430 years, averaging almost 23.0 years of service per executive, having 10.22 employees per reported executive. Break down of Syndax Pharmaceuticals' management performance can provide insight into the company performance.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Syndax Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Syndax Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Syndax will maintain a workforce of slightly above 180 employees by December 2024.
 
Covid

Syndax Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8188) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to drop to -0.44 in 2024. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 33.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 646 K in 2024.
Common Stock Shares Outstanding is likely to drop to about 38.8 M in 2024. Net Loss is likely to rise to about (127.7 M) in 2024

Syndax Pharmaceuticals Workforce Comparison

Syndax Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,969. Syndax Pharmaceuticals holds roughly 184 in number of employees claiming about 5% of equities under Health Care industry.

Syndax Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Syndax Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2023-09-01
0.6
6
10
 189,572 
 377,420 
2023-06-01
0.5556
5
9
 408,565 
 317,707 
2023-03-01
1.75
21
12
 1,056,736 
 280,831 
2022-12-01
1.3
13
10
 295,833 
 111,260 
2022-09-01
0.6667
18
27
 676,947 
 980,066 
2022-06-01
1.0
6
6
 380,551 
 110,429 
2022-03-01
8.0
16
2
 924,444 
 2,380 
2021-12-01
0.5161
16
31
 317,705 
 684,111 
2021-09-01
0.7143
10
14
 242,947 
 292,718 
2021-06-01
1.25
5
4
 28,576 
 27,218 
2021-03-01
2.375
19
8
 865,043 
 120,794 
2020-12-01
0.5455
6
11
 225,376 
 363,526 
2020-09-01
3.0
3
1
 8,830 
 215,000 
2018-06-01
2.2
11
5
 2,105,500 
 2,015,000 
2017-06-01
7.5
15
2
 105,732 
 5,732 
2017-03-01
8.0
8
1
 671,100 
 125,000 
2016-03-01
0.3333
17
51
 9,781,100 
 13,624,856 

Syndax Pharmaceuticals Notable Stakeholders

A Syndax Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Syndax Pharmaceuticals often face trade-offs trying to please all of them. Syndax Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Syndax Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Neil MDPresident DevelopmentProfile
Luke JDGeneral VPProfile
Luke AlbrechtGeneral VPProfile
Briggs MDHead PresProfile
Steven ClosterChief OfficerProfile
Michael MBACEO DirectorProfile
Steve SabusChief OfficerProfile
Joseph MDMember OfficerProfile
Ronald EvansAdvisor CoFounderProfile
Sharon KlahreVice CommunicationsProfile
Peter BScCoFounder OfficerProfile
Anjali GanguliChief OfficerProfile
Alexander NolteVP OfficerProfile
Kevin McManusChief OfficerProfile
Michael DownesCoFounderProfile
Richard HeymanCoFounderProfile
Catherine MDChief OfficerProfile
Keith CPAChief OfficerProfile

About Syndax Pharmaceuticals Management Performance

The success or failure of an entity such as Syndax Pharmaceuticals often depends on how effective the management is. Syndax Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Syndax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Syndax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.34)(0.36)
Return On Capital Employed(0.41)(0.44)
Return On Assets(0.34)(0.36)
Return On Equity(0.38)(0.40)
Please note, the imprecision that can be found in Syndax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syndax Pharmaceuticals. Check Syndax Pharmaceuticals' Beneish M Score to see the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.

Syndax Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Syndax Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Syndax Pharmaceuticals within its industry.

Syndax Pharmaceuticals Manpower Efficiency

Return on Syndax Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.1M
Net Loss Per Executive11.6M
Working Capital Per Employee2.8M
Working Capital Per Executive29M

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.